Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — JP Morgan Healthcare Conference 2017
22 slides from Aurobindo Pharma's conference presentation, Jan 10, 2017
Slide 1: Stock exchange letter on JP Morgan Healthcare Conference
R AUROBINDO January 9, 2017 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED | BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25 floor, Dalal Street, MUMBAI - 400 051 MUMBAI - 400 001 Company Code No. AUROP
Slide 2: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER JP Morgan Healthcare Conference January 10th, 2017
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 4: Executive Summary
Executive Summary Among the Top-5 listed pharmaceutical companies from India by sales(1) and market capitalization(2) 7th largest generic company by volume in the US; IMS TRx represents greater than 35% growth year over year (3) Broad portfolio of diversified dosage forms including Rx and OTC
Slide 5: Emerged into a leading global generic player
Emerged into a leading global generic player 2006 2016 Revenue US$ 244 million US$ 2.1 billion EBITDA margin (%) 11.1% 23.1% Formulations 16% 79% contribution US Formulations 3% 44% contribution EU Formulations 3% 22% contribution Manufacturing 7 facilities including 3 22 facilities including 11 fac
Slide 6: The Journey So Far…
The Journey So Far… 2013 Commenced marketing specialty injectables in USA Building capabilities in Penem and Oncology 2006-08 Acquired UK based Milpharm 2014 Acquired formulations facility Acquired Western European in US commercial operations from Investment in building Actavis manufactu
Slide 7: Core Strengths
Core Strengths Scale & Operational Customer Leadership Strengths Centricity • Large manufacturing • High vertical integration • Global marketing network facilities inspected by in over 150 countries leading regulatory bodies • Robust and highly scalable formulations • Customer centric approach • Wel
Slide 8: Diversified Revenue Base & Strong Organic growth
Diversified Revenue Base & Strong Organic growth Gross sales ~US$ 1.1 billion FY13 25% CAGR FY16 *major markets include Brazil, South Africa, Ukraine, and Mexico Gross sales US$ Mn 6
Slide 9: Operational Performance Trend
Operational Performance Trend Formulations Filings with Different Regulatory Authorities** Gross sales (US$ Mn) 2,151 2,009 1,367 1,123 1,091 *As per Indian Accounting Standards (Ind AS) introduced from Q1FY17 ; **Includes multiple registrations 7
Slide 10: Financial Performance Trend
Financial Performance Trend EBITDA Margin (%) PAT Margin (%) ** ** Average ROE & ROCE (%) Gross Block & Fixed Asset Turnover ** ** * As per Indian Accounting Standards (Ind AS) introduced from Q1FY17 Gross Block is calculated as Tangible Assets + Intangible Assets – Goodwill 8 **includes sales from
Slide 11: Our Business Segments
Our Business Segments US EU Ranked 7th* Rx supplier as per Among top 15** Gx companies IMS total prescriptions dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics, speciality products UK, Portu
Slide 12: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Dietary Supplements R&D Cumulative ANDA Filings and Approvals Includes 89 Injectables Tentative Approvals include 21 ANDAs approved under PEPFAR Unit wise ANDA Filings as on
Slide 13: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Gross Sales (US$ Mn) Growth Drivers in the next 3-4 years Broadening portfolio with more balance through accelerated growth in injectable, OTC, and higher complexity products Increasing collaboration across the global customer base Op
Slide 14: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India Focused on difficult to develop API, niche oral, sterile and specialty injectable Concentrating on wide range of Oncology, Hormonal products, Penems, Enzymes, Biocatalysts, vaccines and Peptides Developing diverse p
Slide 15: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe Gross Sales** Operations in 9 countries with full fledged sales force & support infrastructure Significant presence and position in Top 5 EU market
Slide 16: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Dermatology 5% Others 10% Antineo plastic CV & Resp 7% 27% Digestive 15% CNS 22% Anti-infective 14% Channels Gx BGx OTC Hx TGx 6 Countries (DE, Germany, Geographies All 9 countries 7 countries ES, FR, NL, PT,
Slide 17: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Gross Sales (US$ Mn) Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients Well integrated supply chain management services and logistics for ARV supplies
Slide 18: Growth Markets Business Overview
Growth Markets Business Overview Canada Ukraine GCC Countries Myanmar Mexico Tanzania Colombia Brazil South Africa Growth markets Growth Drivers in the next 3-4 years Gross Sales (US$ Mn) 11% CAGR Build branded generics presence Enhance penetration in selected markets through local manufacturing
Slide 19: The Base Business: API
The Base Business : API Strong Regulatory Capability* API business continue to focus on high value, specialty, small/mid- size products with a limited competition Ensures quality & Reliability of supplies and ability to command cost efficiencies as well as economies of scale 404 Focus on conti
Slide 20: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (US$ Mn) Mar-15 Mar-16 Sept-16 Fx Loan restated 690 748 586 Rupee Loan 6 7 5 Sales Tax Deferment 9 6 0 690 748 586 Gross Debt 705 762 591 Cash Balance 72 122 107 Net Debt 633 640 484 Finance Cost 1.9% 1.8% 1.7% Net Debt / EBITDA & Net Debt / Equity Fx Debt and
Slide 21: Initiatives to Support Sustainable Future Growth
Initiatives to Support Sustainable Future Growth Short Term Medium Term Long Term Focus on strengthening the Portfolio, Commercial Drivers: Focus on launches Focus on increasing and sustaining the Capability and Capacity as Growth Drivers Peptides number of filings on and launches of Additional pr
Slide 22: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register
Aurobindo Pharma — JP Morgan Healthcare Conference 2017 on 6ix